Summary.-Eleven groups of workers submitted a total of 21 bronchial tumourassociated antigen preparations and 19 antisera for comparative studies. Many of the antisera proved to be polyspecific despite absorption procedures. Most of the antigen preparations contained some material reactive towards a reference antiserum to normal human serum proteins.
VARIOUS groups of workers have reported attempts to identify antigenic markers for bronchial cancer. The possibility arose that different groups might not be aware that they were studying similar substances. Also, it was possible that some groups might have found more promising leads in this field which others would wish to follow. Under the auspices of the International Agency for Cancer Research, groups known to be working in this field (see Table I ) were invited to submit antigens and antisera for comparative studies, the preliminary results of which were then presented at a workshop held at Charing Cross Hospital, London, on 7 September 1979.
The specific objectives were to determine any cross-reactivities that might exist between different antigen preparations when precipitated with (a) antisera provided by the participants to their own antigens, and (b) antisera raised to known proteins, e.g. CEA. The possible presence of antibodies to normal human serum pro-33 teins in the antisera was also investigated.
MATERIALS AND METHODS
Antigen samples.-The 21 antigen samples submitted for the study are listed in Table II , which indicates that these extracts were made from bronchial tumours of different histological types, or their associated effusion, or from tumour cell lines; the methods of extraction can also be seen to be diverse.
The samples were stored at -20°C and thawed and kept at 4°C during use, before re-freezing.
Antisera.-The 19 antisera submitted by the participants are listed in Table III (Nos 1-19). These were raised to extracts as described in Bell & Seetharam (1976 ), Gaffar et al. (1979 , Gennings et al. (1979 , Gropp et al. (1979 , Ibrahim et al. (1980) , Lamerz et al. (1979) , McIntire & Sizaret (1974) , Mohr et al. (1974) , Veltri et al. (1977 ), Wolf (1978 . In the case of Ford et al. (1980) , the antisera were raised to viable bronchial tumour cells in culture. It may be noted that there are wide differences in the normal tissues with which Electroimmunoprecipitation.-Two methods of electrophoretic separation were used: (1) Fused-rocket immunoelectrophoresis (IEP), (2) crossed IEP with intermediate gel.
The methods are described in Axelsen et al. (1973) .
Glass plates (10 x 10 cm, 7 x 10 cm or 5 x 7 cm) were spread to a thickness of 1-5 mm with agarose (type HSA; electroendosmosis Mr= -0413; Litex, Glostrup, Denmark). Tris-Barbital buffer was used in the electrophoresis (pH 8-6; ionic strength 0 02).
Sections of gel to which antibody was added generally contained between 1-7 and 3.3%
antiserum.
The antigen wells punched in the gel were filled with 5 ,u antigen solution. Concentrations used were those recommended by each participant to ensure precipitation.
The majority of the fused rocket plates had 21 holes punched along one side containing the 21 antigen samples. Each plate had present in the gel one of the antisera under investigation.
First-dimension electrophoresis in crossed IEP was carried out at 10 V/cm until a bromophenol-stained albumin marker had migrated a suitable distance, and seconddimension electrophoresis (and fused-rocket IEP) at 2 V/cm overnight. After electrophoresis the plates were pressed, washed for 10 min in 01M NaCl, pressed, dried and stained with Coomassie brilliant blue R.
RESULTS
All 21 antigens were screened by fusedrocket IEP against all antisera (19 provided by participants and 10 raised to known proteins, as listed in Table III) .
The precipitates which were formed between the antisera and antigens in these fused-rocket experiments were noted; in some cases more than one precipitate was formed by the reaction of one antigen sample with one antiserum.
The probability of two antisera being identical (same specificities and titres) is very high if two fused-rocket plates, produced by two different antisera look identical when a large panel of antigen sample is compared.
An example of antisera with common specificities is evident when Figs 1 and 2 are compared.
In Fig. 1 the gel contains anti-ferritin (a-ferritin; antiserum 24; ab 24) and characteristic heavy-staining peaks are produced by antigen (ag) nos 1, (6), 8, 9, 10, 12, 13, 15, 18 and 19: these are seen to be reproduced in Fig. 2 By defining the antisera with which an antigen sample forms a precipitate, its components can be "finger-printed", and these are summarized for each antigen in Table IV .
Different types of precipitates were often discernible. For example, in Fig. 3 , where ab 15 (Ikeda a-TS,2 absorbed) is present in the gel, ag 11, 12 and 13 form a pointed, fuzzy precipitate which differs from the pointed but distinct peak produced by ag 2; of different morphology again is the rounded precipitate formed by ag 11, 12, 13, 15 and 16, while a fourth type is seen in the small precipitate produced by ag 9, 12 and 13.
CEA-like activity
As indicated in Table 1V , several of the antigens demonstrated CEA-like activity. This is apparent in Fig. 4 This type of screening for known proteins is very useful in estimating "known" proteins from a heterogeneous preparation. Apparently distinct antigen-antibody reactions Table V presents a summary of the content of antibody specificities in the participants' antisera. As would be expected when antisera have been raised against only partially purified preparations, antibodies are in some cases present not only ii "al-Nordquist" iii "al-Gennings" iv + 2 other undefinable reactivities + very weak reaction with Ag 18 "a-Nordquist" + very weak reaction with Ag 18 i "fa-CEA"
ii "a-Nordquist" iii "a-Gennings" iv + very weak reaction with Ag 18 possible slight reaction with Ag 18 possible slight reaction with Ag 18
Immunodiffusion studies indicated reactivity with Ag 18 (not confirmed by IEP) As for Ab 7 al-MR.l (Gropp) At least two different reactivities:
i High mobility peaks are produced by antimacroglobulin ii Low mobility peaks at least one other undefinable species of antibody "f-Wolf A" "Ikeda ag TS.2" is a distinct antigen, also occurring in the samples submitted by Ibrahim (ag 11) and Lamerz (ag 15). 8 Lamerz ag LCAA-1 was confirmed to be ferritinlike. LCAA-2 was confirmed to be lactoferrin-like. LCAA-3 was confirmed to be CEAlike. As such, these antigens occurred in several of the other antigen samples (see Table IV ). Due to the polyspecific nature of ab 16, 17 and 18, it is difficult to draw conclusions as to which ag samples contain antigens similar to those of Lamerz.
9 "Gennings ag" is a distinct antigen occurring also in Lamerz ag 19 (and possibly in ag 18). 10 "Nordquist ag" is a unique antigen of high mol.
wt. Ford ab 3 reacts specifically with this antigen.
to the appropriate antigen but also to other proteins; these have been identified where possible, and it is interesting that in some instances these include the "marker" investigated by another group. In Table IV , the "identified" antigens found to be components of the antigen samples in each case are set out: Table VI extends these results to incorporate more data, and also indicates where antigens
were not demonstrable at all by these techniques. This leads to the conclusion that in these experiments 5 bronchial tumour-associated reactions are evident, which are distinct from already-known markers and from normal human serum proteins. By reference to Tables IV and VI it can be concluded that the 5 distinct antigens are as follows: It was not possible in the experimental conditions used in these studies to demonstrate the activity of all of the antigens and antisera. In some cases insufficient material was available.
Where activity was demonstrated, it was found that in some cases an antigen studied by a participating group was also present in the tumour extracts of other groups, as indicated in Table IV . Despite this there was no evidence that a single antigen was the focus of study by more than one group. The study illustrated also the difficulties of comparing many partially purified reagents. The presence of several antigens in the preparations reflects to some extent the limitation of absorbed polyvalent antisera as tools for defining unique antigenic determinants.
However, by identifying some of the contaminating proteins with the aid of fused-rocket IEP, and the use of immunoabsorbent subtraction, further progress can be made. For example, as a result of identifying an anti-ac2-macroglobulin in antiserum 10 the development of an assay for Wolf antigen A in human serum has been facilitated (Wolf et al., 1981) .
Whether any of the 5 distinct antigens defined in these bronchial-carcinoma extracts will prove to be clinically useful, has yet to be determined. Not one of them has so far established a dominant claim for wider attention.
The difficulties resulting from the use of conventional antisera in defining tumour markers serve to emphasize the attractions of monoclonal antibodies as tools in this type of work.
